Literature DB >> 15242863

Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.

Francine K Welty1, Alice H Lichtenstein, P Hugh R Barrett, Gregory G Dolnikowski, Ernst J Schaefer.   

Abstract

OBJECTIVE: Our purpose was to determine the relationship between apolipoprotein (apo) A-I and apoB-48 and apoB-100 metabolism in moderately hypercholesterolemic humans. METHODS AND
RESULTS: The kinetics of apoA-I within high-density lipoprotein (HDL), apoB-48 and apoB-100 within triglyceride-rich lipoproteins, and apoB-100 within intermediate-density lipoprotein and low density-lipoprotein (LDL) were examined with a primed constant infusion of [5,5,5-(2)H(3)] leucine in the fed state (hourly feeding) in 23 subjects after consumption of a 36% total fat diet. Lipoproteins were isolated by ultracentrifugation; apolipoproteins by SDS-PAGE gels; and isotope enrichment assessed by gas chromatograph/mass spectrometry. Kinetic parameters were calculated by multicompartmental modeling of the data with SAAM II. ApoA-I production rate (PR) was correlated with LDL apoB-100 pool size (PS; r=0.49; P=0.017) and LDL cholesterol (r=0.61; P=0.002), whereas apoA-I fractional catabolic rate (FCR) was inversely correlated with apoB-48 FCR (r=-0.40; P=0.05) but not with very low-density lipoprotein apoB-100 FCR.
CONCLUSIONS: Two links exist between apoA-I and apoB kinetics: 1) when LDL apoB-100 PS is high, there is increased apoA-I PR; and 2) delayed chylomicron remnant clearance (represented by apoB-48 FCR) is associated with enhanced apoA-I FCR, a finding indicating that alterations in intestinal lipoproteins may be more important in determining HDL cholesterol levels than changes in liver lipoproteins. Using stable isotopes in humans, 2 links were observed between apoA-I and apoB kinetics: (1) when LDL apoB-100 PS is high, there is increased apoA-I PR; and (2) delayed chylomicron remnant clearance is associated with enhanced apoA-I FCR, indicating that alterations in intestinal lipoproteins may be more important in determining HDL-C levels than changes in liver lipoprotein particles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242863     DOI: 10.1161/01.ATV.0000137975.14996.df

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  The inhibition of cholesteryl ester transfer protein: a long and winding road.

Authors:  Kerry-Anne Rye; Philip J Barter
Journal:  J Lipid Res       Date:  2012-04-10       Impact factor: 5.922

Review 2.  Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.

Authors:  Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2006-09-01       Impact factor: 5.922

3.  Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

Authors:  Chunyu Zheng; Katsunori Ikewaki; Brian W Walsh; Frank M Sacks
Journal:  J Lipid Res       Date:  2006-05-09       Impact factor: 5.922

4.  Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women.

Authors:  Stefania Lamon-Fava; Borbala Postfai; Margaret Diffenderfer; Carl DeLuca; John O'Connor; Francine K Welty; Gregory G Dolnikowski; P Hugh R Barrett; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-12-08       Impact factor: 8.311

5.  Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects.

Authors:  Seiko Otokozawa; Masumi Ai; Margaret R Diffenderfer; Bela F Asztalos; Akira Tanaka; Stefania Lamon-Fava; Ernst J Schaefer
Journal:  Metabolism       Date:  2009-07-09       Impact factor: 8.694

6.  Effect of body mass index on apolipoprotein A-I kinetics in middle-aged men and postmenopausal women.

Authors:  Francine K Welty; Alice H Lichtenstein; Stefania Lamon-Fava; Ernst J Schaefer; Julian B Marsh
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

7.  Glycation Reduces the Stability of ApoAI and Increases HDL Dysfunction in Diet-Controlled Type 2 Diabetes.

Authors:  Sangeeta R Kashyap; Abdullah Osme; Serguei Ilchenko; Makan Golizeh; Kwangwon Lee; Shuhui Wang; James Bena; Stephen F Previs; Jonathan D Smith; Takhar Kasumov
Journal:  J Clin Endocrinol Metab       Date:  2018-02-01       Impact factor: 5.958

8.  Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women.

Authors:  F Magkos; B S Mohammed; B Mittendorfer
Journal:  Int J Obes (Lond)       Date:  2008-09-09       Impact factor: 5.095

9.  Using mass measurements in tracer studies--a systematic approach to efficient modeling.

Authors:  Rajasekhar Ramakrishnan; Janak D Ramakrishnan
Journal:  Metabolism       Date:  2008-08       Impact factor: 8.694

10.  Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Authors:  Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2009-01-22       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.